Kerala State Drugs planning to set up Drugs Project in Kerala

Kerala State Drugs & Pharmaceuticals Limited (KSDP) intends to establish a new Oncology Drugs Project in Alleppy, Alappuzha. The project is estimated to take three years to complete and will have an annual production capacity of six crore tablets, 4.5 crore capsules, and 37 lakh intravenous drugs. The Kerala Infrastructure Investment Fund Board (KIIFB) is funding the project, which is expected to cost $231 million. The KSDP has already purchased the project's site and is finalizing the design and construction plans. The KSDP's Oncology Drugs Project is a major endeavour to make cancer drugs more affordable and accessible to Kerala residents. The project will also serve to grow the state's pharmaceutical industry and create jobs. Since 1974, the KSDP has been manufacturing and supplying important and life-saving medications as a public sector venture. 

The organization has a long history of excellence and has received numerous national and international accreditations. The Oncology Drugs Project represents a significant achievement for the KSDP and demonstrates the company's dedication to provide inexpensive and high-quality healthcare to the people of Kerala. Here are some of the benefits of the Oncology Drugs Project for the people of Kerala: Increased access to cancer medicines: 

The project will make cancer medicines more affordable and accessible to the people of Kerala. Improved quality of life: Cancer patients will be able to afford the medicines they need and will have a better quality of life. Boost to the economy: The project will create employment opportunities and boost the state's pharmaceutical industry. Increased research and development: The project will help to promote research and development in the field of oncology. The Oncology Drugs Project is a major step forward for the people of Kerala and will help to improve the quality of life for cancer patients.

As of September 2023, The project is currently in the stage of being approved currently awaiting approval from the government.

News by Rahul Yeligetti